Biogen Inc. (BIIB)
Health Care13 articles
Price chart
Why is BIIB moving today?
+1.1%BIIB is +1.1% today, inside the ordinary range for a session (under 3%). No stories about it reached the feed in the last 24 hours.
What this does not prove. A story on the same day is evidence of timing, not of cause: it explains a move only if it accounts for the size and the direction, and most single-stock moves carry a sector or index component too. Nothing here is a forecast.
Source: Yahoo Finance - quote as of 13 hours ago
Biogen Inc. (BIIB) overview
Biogen is a biotech focused on neurological diseases.
BIIB is a member of the S&P 500. It sits in the Health Care sector. That sector covers pharmaceutical, biotech, device and managed-care companies.
Biogen Inc. trades on the NasdaqGS under the ticker symbol BIIB. The most recent market data puts the share price at about $235.35. That is up 1.08% on the session. At that price the company is worth roughly $34.77B.
Over the past 52 weeks, BIIB has traded between $138.00 and $240.99. Shares change hands at a trailing price-to-earnings (P/E) ratio of about 40.6. The P/E ratio sets the share price against a year of earnings. A higher number means the market is paying more for each dollar the company earns.
Key statistics
Source: Yahoo Finance - quote as of 13 hours ago
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Why investors watch BIIB
BIIB is one of the larger names in the Health Care sector, so investors follow it closely. It tends to move with the rest of the sector. This page sums up each BIIB story as it breaks, and tags it bullish, bearish or neutral.
What moves BIIB
- Earnings. BIIB reports results four times a year. A surprise against the estimate tends to move the stock that day.
- Analyst calls. Upgrades, downgrades and new price targets change what the market expects from BIIB.
- Sector news. Health Care stocks often move together, so a rival's news can move BIIB too.
Market Mood
This week for BIIB
1 story about Biogen Inc. in the last 7 daysFollow BIIB without checking every day
One email every Monday with the week's biggest moves and the stories behind them. Free, unsubscribe anytime.
Latest BIIB news
Stocks to Watch: Salesforce, First Solar, Biogen Lead Premarket
Salesforce (CRM), First Solar (FSLR), and Biogen (BIIB) are among the companies experiencing notable premarket stock movements. Investors are closely watching these stocks for their early trading activity. Salesforce has seen a significant premarket movement, suggesting investor anticipation for potential developments or announcements. First Solar and Biogen are also making headlines due to notable changes in their stock prices ahead of market opening. These premarket movements matter because they can set the tone for trading during the day, impacting investor strategies and market sentiment.
Read More: Stocks to Watch: Salesforce, First Solar, Biogen Lead Premarket
XLV vs PBE: Comparing Two Healthcare ETFs for Investors
The State Street Health Care Select Sector SPDR ETF (XLV) has an expense ratio of 0.08% and offers a yield of 1.6%, while the Invesco Biotechnology & Genome ETF (PBE) has a 0.58% expense ratio and a yield of 1.7%. XLV includes 60 holdings like Eli Lilly & Co (NYSE:LLY) at 16.5% and Johnson & Johnson (NYSE:JNJ) at 10.6%. In contrast, PBE holds 30 companies, with Vertex Pharmaceuticals (NASDAQ:VRTX) at 5.2% and Biogen Inc (NASDAQ:BIIB) at 5.1%. This comparison helps investors weigh low-cost sector exposure versus targeted growth potential in biotechnology.
Read More: XLV vs PBE: Comparing Two Healthcare ETFs for Investors
Biogen (BIIB), Vertiv, GE HealthCare Stocks Make Premarket Moves
Stocks of Biogen (BIIB), Vertiv, GE HealthCare, and Generac experienced notable movements in the premarket. Specific percentage changes and trading volumes are not provided, but their fluctuations can indicate investor sentiment ahead of the market opening. Monitoring these stocks can offer insights into market trends and possible reactions to upcoming earnings or news. Understanding these movements is crucial for investors to make informed decisions based on market performance.
Read More: Biogen (BIIB), Vertiv, GE HealthCare Stocks Make Premarket Moves
Biogen Stock Surges Today Amid Market Interest and Activity
Biogen's stock is experiencing a rally today, though specific figures related to the price movement are not disclosed. The increase follows heightened market interest, but the article does not provide details about trading volumes or percentage changes. There are no concrete data points to indicate why this rally is occurring or its implications for investors. Market participants should monitor Biogen (BIIB) developments, as the lack of detailed data leaves uncertainty regarding this movement's sustainability.
Read More: Biogen Stock Surges Today Amid Market Interest and Activity
Biogen (BIIB) Buy Rating Reiterated After RayThera Acquisition
Needham has reiterated a Buy rating on Biogen (BIIB) following its acquisition of RayThera. This acquisition aligns with Biogen's strategic focus on expanding its offerings in neurodegenerative diseases. Needham has highlighted the potential for increased market share and revenue growth post-acquisition. Such strategic moves may positively influence investor confidence and stock performance for Biogen.
Read More: Biogen (BIIB) Buy Rating Reiterated After RayThera Acquisition
Biogen (BIIB) Stock Upgrade Due to Pipeline Outlook
Needham has upgraded Biogen (BIIB) due to optimism surrounding its pipeline. While specific figures related to the target price or P/E ratios were not disclosed, upgrades can indicate potential growth in stock value and investor confidence. This action is significant as it may lead to increased trading volume and interest in Biogen shares. Market responses to upgrades often correlate positively with future price movements.
Read More: Biogen (BIIB) Stock Upgrade Due to Pipeline Outlook
Biogen (BIIB) Shares Fall 6% After Alzheimer’s Drug Trial Results
Biogen (BIIB) shares dropped 6% following the announcement of positive data from an Alzheimer's drug trial. The trial outcomes, while favorable, did not meet market expectations for immediate approval or broader commercial viability. This decline reflects investor skepticism regarding the drug's potential impact on revenue growth and market positioning. The market will be watching closely for further developments that could influence Biogen's stock performance.
Read More: Biogen (BIIB) Shares Fall 6% After Alzheimer’s Drug Trial Results
Premarket Stocks: Versant, Biogen, Cisco Moves and Impacts
Premarket trading saw significant movements in stocks such as Versant, Biogen, and Cisco. The specifics of the price changes or trading volumes were not indicated in the article. These price movements often reflect investor sentiment and can lead to changes in market valuations. Monitoring these stocks can provide insights into broader market trends, especially around earnings reports or other significant corporate announcements.
Read More: Premarket Stocks: Versant, Biogen, Cisco Moves and Impacts
Biogen (BIIB) Stock Upgrade: Target Raised to $225 from UBS
UBS has upgraded Biogen (BIIB) stock, citing favorable pipeline catalysts as a key reason. The target price for Biogen shares has been raised to $225. This adjustment reflects confidence in the company's growth potential and anticipated drug approvals. The upgrade may positively influence market perception and investor interest in Biogen moving forward.
Read More: Biogen (BIIB) Stock Upgrade: Target Raised to $225 from UBS
Apellis (APLS) Stock Rating Downgraded After Biogen Acquisition
Roth/MKM downgraded Apellis Pharmaceuticals (APLS) following Biogen's acquisition, citing concerns over competitive pressures. This action reflects broader market sentiment regarding APLS's growth prospects in the wake of the acquisition. Specific data points and projections were not included in the downgrade, leading to uncertainty among investors. The market will be closely monitoring APLS's response and performance in the coming quarters, impacting stock movements and investor confidence.
Read More: Apellis (APLS) Stock Rating Downgraded After Biogen Acquisition
Biogen (BIIB) to Acquire Apellis for $5.6 Billion
Biogen (BIIB) announced plans to acquire Apellis Pharmaceuticals for $5.6 billion. This acquisition aims to enhance Biogen's portfolio in the neurological disorders market. The transaction is expected to be finalized in the second half of 2024, pending regulatory approvals. This move may increase Biogen's market presence and influence, reflecting its strategy to diversify and grow its offerings post patent expirations of major products.
Read More: Biogen (BIIB) to Acquire Apellis for $5.6 Billion
Apellis (APLS) Stock Rating Cut by Cantor Fitzgerald Post-Biogen Deal
Cantor Fitzgerald has downgraded Apellis Pharmaceuticals (APLS) following Biogen's recent acquisition. This decision reflects potential market implications for APLS shares amidst Biogen's active strategic moves. The downgrade is a response to shifts in market sentiment influenced by M&A activities. Investors may want to monitor how this impacts APLS's trading volumes and price movements in the near term.
Read More: Apellis (APLS) Stock Rating Cut by Cantor Fitzgerald Post-Biogen Deal
Biogen Reports Positive Phase 2 Results for Lupus Drug: Potential Market Impact
Biogen announced positive results from its Phase 2 clinical trial for a lupus skin drug. The study indicated significant efficacy in treating the condition, although specific metrics on improvement were not provided. The positive outcomes could potentially influence market perceptions regarding Biogen’s pipeline and future drug approvals. The implications for market sentiment and Biogen's stock performance may be notable as a result.
Read More: Biogen Reports Positive Phase 2 Results for Lupus Drug: Potential Market ImpactMore Health Care stocks
Frequently asked questions
Is Biogen Inc. in the S&P 500?
Yes. Biogen Inc. trades as BIIB and is a member of the S&P 500. The index lists it in the Health Care sector.
What sector is BIIB in?
BIIB sits in the Health Care sector of the S&P 500.
Where can I find the latest BIIB news?
Right here. This page collects recent BIIB news and market analysis. Every story gets an AI summary and a bullish, bearish or neutral tag.
What is Biogen Inc.'s stock price?
BIIB last traded at about $235.35. Prices move all through the session, so this is the latest quote rather than a live one.
What is Biogen Inc.'s market cap?
BIIB is worth roughly $34.77B. Market cap is the share price times the number of shares outstanding.
What is BIIB's P/E ratio?
BIIB trades at a trailing P/E ratio of about 40.6. The ratio compares the share price with earnings per share over the past year.